According to Lilly,
had indicated it was ready to launch its version of Evista before outstanding patent litigation had been resolved. The U.S. District Court for the Southern District of Indiana is hearing the matter.
"We appreciate the Court issuing the temporary restraining order and look forward to completing the trial and vindicating our patent rights," said Robert A. Armitage, senior vice president and general counsel for Lilly.
It's been a busy few months for Teva in terms of generic-drug efforts. Last month, Teva announced it had received final FDA approval for a generic version of
migraine drug Imitrex, and in January it received approval for a version of
's antipsychotic agent Risperdal. And in late December, the FDA granted tentative approval to market a version of
Lilly shares were recently up 6% to $29.66. Teva shares were down 0.2% to $43.16.